AIM ImmunoTech (AIM) News Today → Why June 30 Will Be the Tipping Point for AI (From Banyan Hill Publishing) (Ad) Free AIM Stock Alerts $0.44 +0.06 (+15.79%) (As of 06/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 3, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break SeriesMay 31, 2024 | globenewswire.comAIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct OfferingMay 20, 2024 | globenewswire.comAIM ImmunoTech to Participate in Two Upcoming Investor ConferencesMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline ProgressMay 17, 2024 | finance.yahoo.comQ1 2024 AIM ImmunoTech Inc Earnings CallMay 17, 2024 | msn.comAIM ImmunoTech Inc. (AMEX:AIM) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | investorplace.comAIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024May 16, 2024 | globenewswire.comAIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | msn.comAIM ImmunoTech Q1 2024 Earnings PreviewMay 9, 2024 | globenewswire.comAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastMay 8, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 30,865 SharesMay 6, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®May 6, 2024 | baystreet.caAIM Completes Ampligen TurnoutMay 6, 2024 | globenewswire.comAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®April 29, 2024 | globenewswire.comAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerApril 25, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentApril 15, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 15, 2024 | globenewswire.comAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 11, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentApril 10, 2024 | markets.businessinsider.comAim ImmunoTech Announces Positive Data From Ampligen Study In Combination With PembrolizumabApril 10, 2024 | globenewswire.comAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerApril 5, 2024 | ca.news.yahoo.comNearly 600 cars recovered in sweeping auto theft crackdown in Ontario, Quebec: policeApril 4, 2024 | investing.comEarnings call: AIM ImmunoTech optimistic on Ampligen's future in oncologyApril 3, 2024 | insidermonkey.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 AIM ImmunoTech Inc Earnings CallApril 2, 2024 | markets.businessinsider.comAIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023April 2, 2024 | globenewswire.comAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comAIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 26, 2024 | globenewswire.comAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastMarch 25, 2024 | globenewswire.comAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchMarch 23, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) Director Purchases $15,000.18 in StockMarch 22, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 20, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 19, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 37,879 SharesMarch 15, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityMarch 9, 2024 | investing.comAIM ImmunoTech launches CEO Corner for direct stakeholder engagementMarch 7, 2024 | globenewswire.comAIM ImmunoTech Announces Launch of CEO Corner PlatformFebruary 29, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateFebruary 29, 2024 | globenewswire.comAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline DevelopmentsFebruary 15, 2024 | msn.comAIM ImmunoTech commences dosing in pancreatic cancer therapy trialFebruary 14, 2024 | finance.yahoo.comAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerFebruary 14, 2024 | globenewswire.comAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic CancerFebruary 10, 2024 | msn.comAIM ImmunoTech Touts Ampligen’s Post-COVID Study SuccessFebruary 9, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID ConditionsFebruary 8, 2024 | msn.comAIM stock dips amid mixed results for post-COVID fatigue therapyFebruary 5, 2024 | benzinga.comAIM ImmunoTech Stock (AMEX:AIM) Dividends: History, Yield and DatesFebruary 2, 2024 | finance.yahoo.comPRISM MarketView Marks World Cancer DayJanuary 26, 2024 | msn.comAIM ImmunoTech Discloses Q1 Pancreatic Cancer Program Update Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address A Wave of Creative Destruction Set to Strike June 30 (Ad)You have until June 30 … then all hell will begin to break loose… The White House and Goldman Sachs predict generative AI will soon replace up to 300 MILLION jobs — one in every four careers … worldwide. Click here for details. AIM Media Mentions By Week AIM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼0.000.73▲Average Medical News Sentiment AIM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼21▲AIM Articles Average Week Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BCAB News PASG News GRTS News CGTX News TIL News ATRA News TSBX News AVRO News CVM News DYAI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AIM) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored